Skip to content

Home
Resources
Contact Us

Company
Products
- Cardiovascular
- Institutional
  - FIRVANQ^® (Anti-Infective)
  - Xatmep^® (Oncology, Rheumatology)
Pipeline
Compounding Kits

Select Page

AZURITY RESPONSE TO COVID-19

AZURITY PHARMACEUTICALS? RESPONSE TO T HE CORONAVIRUS (COVID-19) PANDEMIC

Home

Company

About Us
Company Culture
Management Team
Board of Directors

Products

Epaned^®
Katerzia^®
Qbrelis^®
FIRVANQ^®
Xatmep^®

Pipeline

Compounding Kits

FIRST^® Lansoprazole
FIRST^® Omeprazole
FIRST^® BLM Mouthwash
FIRST^® Baclofen
FIRST^® Metronidazole
FIRST^® Progesterone

Resources

Azurity Solutions
News & Events
Compliance
Medical Information
Careers

Contact Us

Terms of Use
Privacy Policy and Cookie Notice
Web Accessibility Policy

Azurity Pharmaceuticals, Inc. was formerly known as known as CutisPharma, Inc., parent company of Silvergate Pharmaceuticals, Inc. Product labeling, packaging, and imagery are for representation purposes only and may reflect Azurity, CutisPharma, or Silvergate.

The Information contained herein, including product information, is intended only for residents of the United States.

© 2019 – 2021 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. WEB-AZ-4.1